Kirjoita osake tai kryptovaluutta hakupalkkiin saadaksesi yhteenvedon
Panbela Therapeutics Inc
PBLAPanbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of disruptive therapeutics for the treatment of patients with urgent unmet medical needs. The company's lead product candidates are Ivospemin (SBP-101), a proprietary polyamine analogue, which has completed Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma; Flynpovi, a combination of eflornithine (CPP-1X) and sulindac which is in Phase III clinical trials; and Eflornithine, an enzyme-activated irreversible inhibitor of the enzyme ornithine decarboxylase, currently under Phase I/II trial. It has a research agreement with the Johns Hopkins University School of Medicine for the development of ivospemin. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was incorporated in 2011 and is based in Waconia, Minnesota. Address: 712 Vista Boulevard, Waconia, MN, United States, 55387
Analytics
WallStreetin tavoitehinta
500 USDP/E-suhde
0.003Osinkotuotto
–Kuluva vuosi
Edellinen vuosi
Nykyinen vuosineljännes
Viimeinen vuosineljännes
Kuluva vuosi
Edellinen vuosi
Nykyinen vuosineljännes
Viimeinen vuosineljännes
Avainluvut PBLA
Osinkoanalytiikka PBLA
Osinkojen kasvu 5 vuoden aikana
–Jatkuva kasvu
–Maksusuhde 5 vuoden keskiarvo
–Osinkohistoria PBLA
Osakkeen arvostus PBLA
Talousasiat PBLA
Tuloksia | 2019 | Dynamiikka |